Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. - Test2 - elhamkhani - TriplyDB

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.

http://www.wikidata.org/entity/Q44150673

about

Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials Thalidomide analogues as anticancer drugs Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.Effects of thalidomide on intracellular Mycobacterium leprae in normal and activated macrophages.Psoriasis induced by thalidomide in a patient with multiple myeloma Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53 Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.Thalidomide and lenalidomide: Mechanism-based potential drug combinations.Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.Thalidomide: a new anticancer drug?Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Novel therapeutic agents under investigation for malignant melanoma.Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.Thalidomide-derived immunomodulatory drugs as therapeutic agents.Thalidomide and immunomodulatory drugs in the treatment of cancer.Future directions in multiple myeloma treatment.Immunomodulatory drugs.Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.Lenalidomide: an immunomodulatory drug.Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.Immunodeficiency and immunotherapy in multiple myeloma.Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.Dermatologic therapeutics: thalidomide. A practical guide.Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo.Lenalidomide in multiple myeloma: current role and future directions.The potential of immunomodulatory drugs in the treatment of solid tumors.Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma.Lenalidomide in solid tumors.Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma.Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.Thalidomide has anti-inflammatory properties in neonatal immune cells.Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.

P2860

Q21089606-2C74CAA8-97CA-4C72-A91A-C3F2AB7B12B3 Q21133524-9832EF2D-FCD6-41AB-B284-9C291DBA5207 Q24670383-10E71650-F173-41F6-B777-2B495B39056C Q28477281-91CFE905-930F-468B-9A44-CC6EC968ED42 Q33398044-3884683D-7A13-4D91-9AAD-495902D6BD03 Q33429608-B712B7F0-3EC6-4167-B314-EE1087270A82 Q33594060-4F7A90E4-0CF4-424B-85B0-C3CD4A2DC2BC Q33833466-22C0F49A-6169-4ACE-979D-D18D24E81C45 Q34137016-880568B9-431A-4246-A12B-0A72BB3820B1 Q34666858-8936BA8A-E7A9-46A5-BBA2-69D25C672115 Q34775475-06D210D2-7916-4E75-B26E-C08A907B26F0 Q35033514-3960A2FA-9638-4A97-BF4E-85BEFB30E7A7 Q35164773-E4614061-78BE-457F-A86F-FBB4FAFBFC4B Q35171777-8501E3CA-E37B-4252-84A8-522D4ADDC92D Q35207632-12810180-9369-4340-985B-9CC2999C9C42 Q35844148-7E6BD62A-9366-4F6F-B61D-A367752BE93F Q35967301-BB90ABAC-4287-4FC8-A169-86B17568C476 Q36040871-8F7D957F-95A6-4A38-B928-FB0428F04F97 Q36258701-C4D30CA0-EB53-4CAD-853C-D2D864068F83 Q36321396-32363805-2E63-4DD2-85BF-734544D3B810 Q36364976-3F630F6E-E940-4D9A-8D86-4E90AEC8262F Q36429554-BD363A18-DD64-4D40-B19D-56A6230FC9B9 Q36646261-6B6518DD-59CD-4B44-8D17-CCF78A64B2AC Q36904977-B1093609-2795-4D13-9547-7DF34E6C1F51 Q36965455-36E669B5-1EB9-42C3-BDEF-D8E4F86B1F35 Q36986014-52190C20-4C93-421D-A344-2A80ECFD5419 Q37282307-1D797443-7EF7-427A-91F0-353DF91A04DD Q37561393-6C5986DA-6097-4D49-8EA7-FC33144F3FA8 Q37704401-3FCDB442-5683-44C1-97CE-2C435694887D Q37797475-157AB260-FFBD-4128-B845-3B2B96DFBCD5 Q37822742-3FB41032-94A8-42B4-833F-5A21A277F438 Q37864686-57244F80-5D00-4F0F-9796-0A5136871989 Q37976672-D48A8097-B7FE-4EEE-93C1-58E9B0251606 Q38010055-B8C1926E-A6D0-492F-B97A-C601C513F510 Q38146900-BC247213-385F-4D1B-87CF-9B95F5572AE3 Q38462720-43F033C8-532D-48FB-9F8F-4D94478BDC1E Q38714708-4D2E978C-2320-4228-8836-0FCBE9CECE5B Q38964255-48E6D2EE-C76E-4C09-ABFF-FA95771816C4 Q39600474-1C10905F-E6EF-4E5A-8B34-A13262B8CF1F Q39654887-7A17B53D-A190-4167-B15C-A3F1E771AAC2

P2860

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.

http://www.wikidata.org/entity/Q44150673

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Thalidomide and its analogues ...... ing co-stimulation of both CD4

@nl

Thalidomide and its analogues ...... oth CD4(+) and CD8(+) T cells.

@en

type

label

Thalidomide and its analogues ...... ing co-stimulation of both CD4

@nl

Thalidomide and its analogues ...... oth CD4(+) and CD8(+) T cells.

@en

prefLabel

Thalidomide and its analogues ...... ing co-stimulation of both CD4

@nl

Thalidomide and its analogues ...... oth CD4(+) and CD8(+) T cells.

@en

P1433

Q44150673-DBB5D44D-1658-46C3-848A-6AB81CBF4533

P1476

Q44150673-01CBC993-7607-4B6C-915D-24E72403939C

P2093

Q44150673-0D26640A-6901-4EEF-8829-D9283E13F1FE

Q44150673-2C14DA3D-48AF-4D21-808D-3D4B2891DCA4

Q44150673-66BA0C53-DC47-45F6-A779-EBFC1DC6F405

Q44150673-BE81AFE2-EB90-444D-A2C1-8027A3869180

Q44150673-DF4B7174-FDEA-4B97-9EB6-E04A90C7D67E

Q44150673-FAA4E199-6407-4D31-ADFD-993C53183F64

P2860

Q44150673-0305FD58-C08C-4CCA-AE29-B25B9D90C982

Q44150673-03EC7E5A-603D-4351-824D-D656E6E330A6

Q44150673-05F1B936-9700-4963-A198-5C7FC36597BD

Q44150673-12FB8492-8215-454E-ABAC-51C665790326

Q44150673-22FFB856-C750-40E4-BEC4-A898B1FC724F

Q44150673-2D9CFA81-DD53-4507-9FBE-EBB52CC06D6D

Q44150673-318D10E1-97D4-4A61-AF9C-1EB29458D286

Q44150673-31930F5D-DB26-44E0-B29F-A9154D1499B9

Q44150673-447BF7FD-6482-4D5D-8624-F26D077921D8

Q44150673-4774BB19-C109-4752-8631-7D3B8542AC66

P304

Q44150673-730070E8-C078-40B4-A43A-03FF88C04642

P31

Q44150673-F4F47948-5A07-4A80-917C-4CE68268AD58

P356

Q44150673-A4E5DF23-A302-4735-9277-7E79E64570B1

P433

Q44150673-F6453B54-8EB4-42F1-98B4-2C1459DEFFE7

P478

Q44150673-9EF7EE09-AABE-4476-BBFF-9D2D43B91D13

P577

Q44150673-556AE1F2-06BC-445E-A4D7-6A35FD4671CF

P5875

Q44150673-96921691-2AB9-4EB2-9A05-D8E20EDF19A1

P698

Q44150673-0816366D-9A1B-4863-B4BF-A299CDBBDD9A

P921

Q44150673-5DB8C7D3-B199-49BD-A534-85533511172A

Q44150673-D1BAE602-6B40-44BE-9818-B7182EA39A4E

P932

Q44150673-EC7FA5FC-6E28-4BEC-9EA4-09AF674B940B

P356

J.1365-2249.2002.01954.X

P1433

Clinical and Experimental Immunology

P1476

Thalidomide and its analogues ...... oth CD4(+) and CD8(+) T cells.

@en

P2093

A G Dalgleish

http://www.w3.org/2001/XMLSchema#string

D Stirling

http://www.w3.org/2001/XMLSchema#string

G Muller

http://www.w3.org/2001/XMLSchema#string

I A Clarke

http://www.w3.org/2001/XMLSchema#string

J B Marriott

http://www.w3.org/2001/XMLSchema#string

K Dredge

http://www.w3.org/2001/XMLSchema#string

P2860

The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity

Thalidomide as an emerging immunotherapeutic agent.

Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group.

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.

Antitumor activity of thalidomide in refractory multiple myeloma.

Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity.

Immunotherapeutic and antitumour potential of thalidomide analogues.

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

P304

75-84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2249.2002.01954.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11126274

http://www.w3.org/2001/XMLSchema#string

P698

12296856

http://www.w3.org/2001/XMLSchema#string

P921

P932

1906488

http://www.w3.org/2001/XMLSchema#string